BioMarin delays planned FDA filing for hemophilia gene therapy
Bio Pharma Dive
MAY 31, 2022
BioMarin now expects to resubmit its approval application to the FDA by the end of September, the latest regulatory setback for the company's closely watched treatment
Let's personalize your content